These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. Duintjer Tebbens RJ; Hampton LM; Thompson KM BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198 [TBL] [Abstract][Full Text] [Related]
35. Safe landing for global polio eradication: a perspective. Arita I; Francis DP Vaccine; 2011 Nov; 29(48):8827-34. PubMed ID: 21959326 [TBL] [Abstract][Full Text] [Related]
36. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Thompson KM; Duintjer Tebbens RJ Expert Rev Vaccines; 2014 Feb; 13(2):221-34. PubMed ID: 24308581 [TBL] [Abstract][Full Text] [Related]
38. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Shimizu H Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090 [TBL] [Abstract][Full Text] [Related]
39. [Inactivated poliovirus vaccines: an inevitable choice for eliminating poliomyelitis]. Vidor JD; Jean-Denis S Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1021-1031. PubMed ID: 28057103 [TBL] [Abstract][Full Text] [Related]